CTMX today
$2.13+$0.15 (+7.58%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourBullish
1 hourStrong Bullish
15 minExpanding
5 minStrong Bullish
Daily trend turns up above $2.61
Key levels
Resistance$2.42
Resistance$2.16
Support$1.90
Support$1.72
Latest news & SEC filings
AnalystWedbush lifts its valuation goal for CytomX Therapeutics to $12
AnalystWedbush keeps Outperform rating on CytomX Therapeutics, lifts target to $12
EarningsCytomX Therapeutics Discusses Third-Quarter 2026 Results on Conference Call
All CTMX news →About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapies using its PROBODY platform, which creates masked biologics that activate specifically in the tumor microenvironment. Its lead product candidate, varsetatug masetecan, is an antibody-drug conjugate targeting EpCAM that is in Phase 1 testing for colorectal cancer and other solid tumors. The company also develops CX-801, a masked interferon alpha-2b, and has research collaborations with several large pharmaceutical companies.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
CytomX Therapeutics, Inc. (CTMX)
What Is the Price Target for CTMX?
SEPT Low Target
$11.00
SEPT Mid Target
$11.00
SEPT High Target
$14.00
Analyst Consensus
$11.00
Is CTMX a Buy or Sell Right Now?
Thesis
- •Revenue growing -44.8% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CTMX.
Start Free Trial →Is CTMX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$9.15
20
Moat Score
NONE
2/9
Piotroski Score
-2.1
Altman Z-Score
What Is Smart Money Doing with CTMX?
Insider Signal
SELLING
0 buys / 5 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| McCarthy Sean A. | director officer | Buy | 101,793 | $162K | Nov 6, 2025 |
| McCarthy Sean A. | director officer | Sale | 101,793 | $462K | Nov 6, 2025 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CTMX Growth Story
Revenue YoY
-44.8%
3yr Revenue CAGR
12.8%
EPS Growth YoY
-139.47%
FCF Growth YoY
12.4%
Revenue Trend
STRONG
Dark Pool Trades for CTMX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CTMX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 10:20:45 | $2.13 | 38,540 | $$82K | SELL |
| 10:19:51 | $2.11 | 38,565 | $$81K | BUY |
| 21:14:03 | $2.14 | 1,000 | $$2K | BUY |
| 21:01:05 | $2.13 | 1,196 | $$3K | BUY |
| 21:00:00 | $2.13 | 1,400 | $$3K | SELL |
5 dark pool trades shown · $$171K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CTMX
PREVIEWSEPT Investing provides real-time options flow tracking for CTMX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $3 | Jan 21 | 436 | $$195 | 3 | SWEEP |
| CALL | $4 | Feb 19 | 100 | $$1140 | 57 | SWEEP |
| CALL | $4 | Feb 19 | 100 | $$1000 | 50 | SWEEP |
| CALL | $4 | Feb 19 | 100 | $$3000 | 200 | BLOCK |
| CALL | $4 | Feb 19 | 100 | $$1500 | 100 | BLOCK |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for CytomX Therapeutics, Inc. (CTMX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CTMX — frequently asked questions
What is CTMX stock price today?
CytomX Therapeutics, Inc. (CTMX) is at $2.13, up 7.58% (+$0.15) at the Nov 11, 2026 close.
Why is CTMX stock moving today?
Latest CTMX news — Nov 6, 2026: Wedbush lifts its valuation goal for CytomX Therapeutics to $12 · Nov 6, 2026: Wedbush keeps Outperform rating on CytomX Therapeutics, lifts target to $12
What is the CTMX price target?
The average analyst price target for CTMX is $11.00, ranging from $11 to $14, based on 3 analysts. Latest: JP Morgan maintains on Aug 13, 2026.
What do analysts rate CTMX?
Analyst ratings for CTMX: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did CTMX beat earnings?
CTMX last reported on Nov 5, 2026: EPS -$0.09 vs -$0.07 expected — a miss of 25.2%.
Does CTMX pay a dividend?
Yes. CTMX's dividend yield is 0.51%.
What are CTMX support and resistance levels?
Support: $1.90, $1.72, $1.42. Resistance: $2.16, $2.42, $2.61.
What are insiders doing with CTMX?
Insider activity: SELLING, 0 buys and 5 sells in the last 90 days.
What is the latest news on CTMX?
Nov 6, 2026: Wedbush lifts its valuation goal for CytomX Therapeutics to $12 · Nov 6, 2026: Wedbush keeps Outperform rating on CytomX Therapeutics, lifts target to $12 · Nov 5, 2026: CytomX Therapeutics Discusses Third-Quarter 2026 Results on Conference Call